These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27404028)

  • 1. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.
    Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Komm BS
    Menopause; 2016 Oct; 23(10):1060-6. PubMed ID: 27404028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
    Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
    Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
    J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
    Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
    Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.
    Pinkerton JV; Pan K; Abraham L; Racketa J; Ryan KA; Chines AA; Mirkin S
    Menopause; 2014 Mar; 21(3):252-9. PubMed ID: 23942245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
    Pinkerton JV; Bushmakin AG; Racketa J; Cappelleri JC; Chines AA; Mirkin S
    Menopause; 2014 Mar; 21(3):243-51. PubMed ID: 23899830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
    Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
    J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.
    Bushmakin AG; Abraham L; Pinkerton JV; Cappelleri JC; Mirkin S
    Menopause; 2014 Aug; 21(8):815-22. PubMed ID: 24378765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
    Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
    Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
    Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
    Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
    Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
    Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
    Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
    Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.
    Pinkerton JV; Pickar JH; Ryan KA; Yu CR; Mirkin S; Komm BS
    Menopause; 2016 Jun; 23(6):611-20. PubMed ID: 27163519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.
    Kagan R; Komm BS; Ryan KA; Lavenberg J; Yu CR; Pinkerton JV
    Menopause; 2016 Nov; 23(11):1204-1213. PubMed ID: 27433860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
    Umland EM; Karel L; Santoro N
    Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.